Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioVectra, a biopharmaceutical company, and Therapure BioPharma have agreed to partner in the development of a PEGylated biologic drug target used for cancer treatments, with a goal of advancing the project to a regulatory filing stage, suitable for a marketing partner to add to its portfolio of biologic products.
Subscribe to our email newsletter
The partnership with Therapure builds upon BioVectra’s expertise in the production of modified biologic molecules using a proprietary MPEG technology.
Therapure, from its 130,000 square feet facilities in Mississauga, Ontario, is said to add proprietary purification techniques and formulation, fill, and finish expertise in biologics handling.
Thomas Wellner, president and CEO of Therapure Biopharma, said: “We are very excited about working with BioVectra. They bring significant expertise in active pharmaceutical ingredient development and a high degree of competence and commitment to our partnership.”